<DOC>
	<DOCNO>NCT00807612</DOCNO>
	<brief_summary>This global , multicenter , 2-part , open-label phase 1b single-arm phase 2 study design evaluate safety efficacy AMG 479 combination paclitaxel carboplatin first-line treatment advance squamous non-small cell lung carcinoma .</brief_summary>
	<brief_title>QUILT-2.017 : Phase 1b/2 Study AMG 479 Combination With Paclitaxel Carboplatin 1st Line Treatment Advanced Squamous Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically cytologically confirm advanced squamous NSCLC Measurable disease define per modify RECIST criterion ECOG performance status 0 1 ≥18 year old Adequate glycemic function , subject know diabetes Untreated symptomatic central nervous system ( CNS ) metastases Prior anticancer therapy follow : Any prior chemotherapy squamous NSCLC ; Any prior adjuvant neoadjuvant chemotherapy squamous NSCLC ; Any prior chemoradiation squamous NSCLC ; Central ( chest ) radiation therapy ≤ 28 day prior enrollment , radiation therapy peripheral lesions≤14 day prior enrollment squamous NSCLC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>AMG 479</keyword>
	<keyword>IGF-1R</keyword>
	<keyword>Apoptosis</keyword>
	<keyword>Monoclonal Antibody</keyword>
	<keyword>Advanced Squamous Non-Small Cell Lung Cancer</keyword>
	<keyword>antibody 1st-line</keyword>
</DOC>